Mounjaro on the NHS – What It Means for You

The NHS Responds to the UK’s Obesity Crisis

A major shift in obesity care began on Monday the 23rd of June 2025, with an official mass rollout of Mounjaro on the NHS across England. The launch marks the first time that GPs can prescribe Mounjaro (tirzepatide), which is being widely used for weight management due to its profound appetite-suppressing effects. The move signals a step change in how the NHS plans to tackle the obesity epidemic, but it also comes with limitations, caveats, and broader implications for UK society.

A Milestone in Weight Loss Treatment: What’s Changed?

Some GLP-1 medicines were previously available on the NHS, however availability was very limited. This has now changed. From 23 June, GPs and primary care providers can now prescribe Mounjaro, expanding reach to more patients especially those with the most urgent health risks associated with obesity.

This expanded access is in line with NICE guidance and forms part of a phased rollout led by NHS England. According to the NHS guidance from NHS England, the move is designed to serve up to 220,000 patients over the next three years, prioritising those with “the greatest clinical need” to begin with.

How Mounjaro Works And Why It’s a Game Changer

Mounjaro, manufactured by Eli Lilly, is a dual-action medication. It mimics two hormones, GLP-1 and GIP,  which help control blood sugar levels, reduce appetite, and slow digestion. Patients taking tirzepatide typically experience significant appetite reduction, leading to sustained calorie reduction, weight loss, and improved cardiometabolic health. In UK trials and international data, people using Mounjaro lost an average of 20% of their body weight after 72 weeks of treatment, exceeding the average of 14% weight loss from Wegovy. Read more about how Mounjaro works here.

How Can I Get Mounjaro From My GP?

Eligibility is currently quite strict. To qualify for Mounjaro on the NHS under the first rollout phase (2025–2026), you must be over 18 years old and meet certain BMI and health factors.

➡️ What BMI Do I Need to Get Mounjaro on the NHS?
To be eligible for Mounjaro through your GP you must have:

• A Body Mass Index (BMI) of 40 or higher
• Or 37.5 or higher if you are from a Black, Asian, or minority ethnic background, due to higher risk at lower BMI levels.

Check your BMI here.

➡️ What Health Conditions Do I Need To Get  Mounjaro from my GP?
In addition to being 18 or over, and having a BMI of 40 or higher, you must have at least four of the following five obesity-related health conditions:

• Type 2 diabetes
• High blood pressure
• Cardiovascular disease
• Obstructive sleep apnoea
• Abnormal blood fats (dyslipidaemia)

Patients must also agree to participate in additional lifestyle support as part of their NHS Mounjaro treatment plan.

If you don’t meet all these criteria, you won’t be eligible through the NHS at this stage, though private access from regulated providers remains available for many. 

Who Will Get It Next? The NHS Rollout Timeline

The NHS rollout is phased to manage demand, with eligibility slowly expanding each year:

• June 2025 – June 2026: BMI of 40+ (or 37.5+ for ethnic minorities) and 4 out of 5 qualifying conditions.
• June 2026 – March 2027: Expanded to people with BMI of 35 - 39.9 and 4 out of 5 qualifying conditions.
• April 2027 onwards: Eligibility widens to include people with a BMI of 40+ and 3 out of 5 qualifying conditions.

According to estimates from NHS England, around 3.4 million people could qualify under later stages, but less than 1% of the UK’s obese population will qualify initially.

Why This Matters: Obesity in the UK

Obesity is now one of the leading causes of ill health in the UK. According to latest NHS data, approximately 29% of UK adults are obese, and the figure is rising. The condition is linked to heart disease, stroke, cancer, type 2 diabetes, and increased risk of hospitalisation.

Speaking on the rollout, Health Secretary Wes Streeting said: “Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic.”

This rollout is seen as a move to shift NHS focus from reactive treatment to prevention, an approach welcomed by many public health campaigners.

Wraparound Support Is Mandatory

Patients prescribed Mounjaro on the NHS won’t just receive a prescription and be sent on their way. All patients must participate in a wraparound support programme, including:

• Nutritional guidance
• Physical activity support
• Behavioural and lifestyle coaching

If a patient refuses wraparound care, they won’t be prescribed the medication, ensuring that treatment is holistic and sustainable.

GPs & Pharmacists Sound the Alarm Over Demand

Despite enthusiasm, concerns about GP workload and system readiness are growing.

“While we recognise the benefits of weight loss drugs, many GPs are concerned about the implications… particularly around workload, training, and capacity to offer wraparound care.”Professor Kamila Hawthorne, Chair of the Royal College of General Practitioners

“We expect to see prescription volumes increase rapidly… however, NHS provision won’t meet demand straight away, so we fully expect that many people will continue seeking it privately.” Olivier Picard, Chair of the National Pharmacy Association (NPA)

This tension highlights the growing divide between clinical ambition and logistical reality, with pharmacies already bracing for stock pressure.

How Does This Affect Supermarkets and Daily Life?

The societal impact is already being felt. A recent Kantar report noted a 0.4% decline in grocery volume in early 2025, the first year-on-year drop in over five years, cutting household grocery spending by 6-9% on average.

Analysts link the shift to the growing use of GLP-1 medications like Mounjaro. As 4% of British households now include a user of weight loss injections (double that of last year), purchases of crisps, chocolates, and sugary drinks are falling. Retailers like Tesco and Sainsbury’s are reportedly reviewing their product line strategies, anticipating more customers reducing their high-calorie snacks.

Early evidence shows the impact extends to alcohol too: “GLP-1 treatment may have a negative impact on alcohol consumption,” notes consulting firm AlixPartners, citing a study of 14,000 WeightWatchers members in which 45% of users who previously drank at least once a week reported cutting back, contributing to an estimated 1–2 % fall in alcohol sales within just six months of starting the medication.

(The underlying behavioural data come from U.S. cohorts, but analysts expect similar patterns in the UK and other markets as adoption spreads.)

Final Thoughts: A Turning Point in Public Health

The rollout of Mounjaro via GPs marks a turning point in how the NHS tackles obesity. It symbolises hope for many who’ve struggled with weight for years, and the promise of more equitable care. But it also exposes the gaps between eligibility and need, and the continued role of private healthcare in filling those gaps.

Our Chief Medical Officer, Dr. Charlotte notes: ”For patients eager to explore Mounjaro, whether via the NHS or private prescription, the key is to stay informed, seek professional guidance, and take a whole-person approach to weight loss.”

What If You Don’t Qualify for Mounjaro on the NHS?

Most people interested in Mounjaro won’t meet the NHS criteria, at least not yet. But that doesn’t mean you’re out of options.

Here’s what you can do:

• Book a consultation privately to discuss your Mounjaro eligibility
• Order Mounjaro online through a regulated pharmacy, if you qualify clinically
• Access lifestyle support programmes that can help with weight management

The key takeaway is that while the NHS rollout is historic, private care remains the most accessible route for the majority of people today.